Published in final edited form as:

Mol Pharm. 2013 September 03; 10(9): 3514–3518. doi:10.1021/mp400164f.

Targeted Delivery of Antisense Oligonucleotides by Chemically Self-Assembled Nanostructures (CSANs)

Amit Gangar[†], Adrian Fegan[†], Sidath C. Kumarapperuma[†], Peter Huynh[†], Alexey Benyumov[‡], and Carston R. Wagner^{*,†,§}

[†]Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55414, USA

[§]Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55414, USA

[‡]Department of Pulmonary, Allergy, Critical Care (PACC), University of Minnesota, Minneapolis, Minnesota 55414, USA

Abstract

Synthetic nucleic acids have shown great potential in the treatment of various diseases. Nevertheless, the selective delivery to a target tissue has proved challenging. The coupling of nucleic acids to targeting peptides, proteins and antibodies has been explored as an approach for their selective tissue delivery. Nevertheless, the preparation of covalently coupled peptides and proteins that can also undergo intracellular release as well as deliver more than one copy of the nucleic acid has proved challenging. Recently, we have developed a novel method for the rapid non-covalent conjugation of nucleic acids to targeting single chain antibodies (scFv) using chemically self-assembled nanostructures (CSANs). CSANs have been prepared by the self-assembly of two dihydrofolate reductase molecules (DHFR²) and a targeting scFv in the presence of bis-methotrexate (bis-MTX). The valency of the nanorings can be tuned from one to eight subunits, depending on the length and composition of the linker between the dihydrofolate reductase molecules. To explore their potential for the therapeutic delivery of nucleic acids as well as the ability to expand the capabilities of CSANs by incorporating smaller cyclic targeting peptides, we prepared DHFR² proteins fused through a flexible peptide linker to cyclic-RGD, which targets $\alpha v\beta 3$ integrins, and a bis-MTX chemical dimerizer linked to an antisense oligonucleotide (bis-MTX-ASO) that has been shown to silence expression of eukaryotic translation initiation factor 4E (eIF4E). Monomeric and multimeric cRGD-CSANs were then prepared with bis-MTX-ASO and shown to undergo endocytosis in the breast cancer cell line, MDA-MB-231, which over-express $\alpha v\beta 3$. The bis-MTX-ASO was shown to undergo endosomal escape resulting in the knock down of eIF4E with at least the same efficiency as ASO delivered by oligofectamine. The modularity, flexibility and common method of conjugation may prove to be a useful general approach for the targeted delivery of ASOs, as well as other nucleic acids to cells.

Corresponding Author: Carston R. Wagner, University of Minnesota, 8-174 Weaver-Densford Hall, 308 Harvard St. SE, Minneapolis, MN-55455, USA. wagne003@umn.edu.

SUPPORTING INFORMATION:

Synthetic methods, characterization, other experimental details, and additional figures. This material is available free of charge via the Internet at <http://pubs.acs.org>

TOC image

Keywords

antisense; delivery; nucleic acid; nanotechnology

Synthetic nucleic acids such as antisense oligonucleotides (ASOs), siRNA, shRNA are being widely studied for the treatment of various diseases such as hepatitis B, hypercholesterolemia and cancer.^{1,2} Currently about 22 oligonucleotide-based drugs are in various stages of clinical trials and many more are in pre-clinical development.^{3,4} A major hurdle associated with the development of nucleic acid, including oligonucleotide-based drugs is their delivery and cellular uptake by the target tissue. The inherent hydrophilicity and charged nature of oligonucleotides are significant barriers to their transport across the hydrophobic cell membranes to their site of action i.e. cytoplasm or nucleus. This limitation was addressed with a number of molecular designs that involve the direct conjugation of oligonucleotides to various cell surface receptor targeted antibodies, peptides, small molecules or aptamers enabling the receptor mediated endocytosis of the oligonucleotides.^{5,6,7,8,9}

Previously, we have reported the targeted cellular delivery of methotrexate-functionalized oligonucleotides to CD3+ T-leukemia cells, through the non-covalent binding of DHFR-antiCD3 scFv fusion proteins.¹⁰ In addition, we have also observed that incubation of a bis-methotrexate ligand (**bis-MTX**) with a fusion protein comprised of two copies of dihydrofolate reductase and an antiCD3 single chain variable fragment (scFv) (DHFR²antiCD3) results in the formation of chemically self-assembled antibody nanorings (CSANs) displaying multiple copies of the antiCD3 scFv.^{11,12} The size of the nanorings formed can be controlled by varying the size of the linker between the two DHFR molecules. If the linker is 13 amino acids long (13DHFR²) monomeric and dimeric nanorings are formed whereas if the linker is 1 amino acid, glycine, (1DHFR²) predominantly octameric nanorings are formed. The antiCD3 CSANs selectively bind to CD3 receptors on the membranes of T-leukemia cells and are endocytosed by a clathrin dependent process.¹² Further, development of the bis-MTX ligand resulted in bis-MTX ligands with a third arm which can be functionalized with oligonucleotides (**bis-MTX-Oligo**).¹⁰ Incubation of **bis-MTX-Oligo** with DHFR²antiCD3 resulted in oligomerization to

form higher order species. We have shown that this oligonucleotide containing CSANs bind specifically to CD3 cell surface receptors on CD3+ T-leukemia cells and undergo internalization. The novelty this approach is the elimination of the need to covalently attach the oligonucleotides to the target ligands and the ability to display multiple copies of oligonucleotide on a single construct. Although this method shows great promise, the ability of oligonucleotides, such as ASO's to be delivered by CSANs and undergo endosomal escape needs to be evaluated.

Eukaryotic translation initiation factor 4E (eIF4E) is the key rate-limiting component in cap-dependent translation – the major mechanism for proteins synthesis within cells.^{13,14} In solid tumors, eIF4E is over-expressed or hyperactivated feeding the oncoprotein addiction of the malignant cells.^{13,15} Graff and others have shown that knocking down eIF4E in cancer cells decreases cell growth, induces apoptosis and increases cell sensitivity towards common chemotherapeutic agents and radiation.^{16,17,18} ASOs targeting eIF4E are currently in clinical development.

RGD4C is a cyclic Arg-Gly-Asp peptide, containing 4 cysteine residues, which has been shown to bind to cell surface integrins, with some specificity for $\alpha v \beta 3$. Integrins such as $\alpha v \beta 3$ are over-expressed on various solid tumors, including head and neck and breast tumors as well as during formation of nascent tumor blood vessels by angiogenesis.^{19,20} The peptide RGD (and analogues) have been used for targeting numerous tumor types, including breast cancer tumors.^{21,22} We hypothesized that chemically induced self-assembly of RGD4C-DHFR nanostructures could be used to display multiple copies of the RGD4C peptide, thus targeting breast cancer cells. These peptide functionalized nanostructures could therefore be used for the specific delivery of ASOs targeting eIF4E causing selective reduction in the expression of eIF4E protein and a general suppression of cap-dependent translation.¹⁶

13DHFR²RGD4C and **1DHFR²RGD4C** proteins were expressed in *E. coli* cells as soluble proteins with the yield of about 20 mg of pure protein per litre culture.²³ Graff and co-workers has previously reported a 20-mer phosphorothioated oligonucleotide containing 2-methoxyethyl modified bases can act as an eIF4E ASO.¹⁶ We obtained a simplified 20-mer phosphorothioated oligonucleotide containing the same sequence and a free 3' -thiol. The 3' -thiol of the oligonucleotide was coupled to the previously reported bis-MTX maleimide and the resulting **bis-MTX-ASO** was used in the present study (Supplementary, Figure S1).¹⁰ **13DHFR²RGD4C** and **1DHFR²RGD4C** was mixed with **bis-MTX-ASO** to form monomeric and multimeric nanostructures respectively (Figure 1a). Analysis of the nanostructures by size exclusion chromatography (SEC) revealed that **13DHFR²RGD4C** (Figure 1b, black line) and the mixture of **bis-MTX-ASO** with **13DHFR²RGD4C** (Figure 1b, red line) has similar retention times (approximately 31 minutes). This indicates that they have similar hydrodynamic radii, thus suggesting the presence of monomeric species. This was further confirmed when we looked the red peak at the MTX absorbance at 302 nm. Excess **bis-MTX-ASO** elutes at approximately 38 minutes. A number of higher order structures (trimers and dimers) are observed eluting at 24–28 minutes. In contrast, similar to previous observation for the oligomerization of **13DHFR²** with **bis-MTX**, when **13DHFR²RGD4C** was incubated with **bis-MTX** dimeric species were formed

predominantly.¹¹ This presumably results from the steric bulk of the 20-mer oligonucleotide causing the formation of smaller rings. A similar change in the size of species formed is observed when, **1DHFR²RGD4C** is incubated with **bis-MTX-ASO** a number of higher order multimeric species ranging from pentamer to heptamer are formed (Figure 1c, red line). However, incubation of **1DHFR²RGD4C** with **bis-MTX** results in the formation of mostly octameric species.

In order to study the ability of CSANs-RGD4C nanostructures to deliver ASOs to the cells by confocal laser scanning microscopy we have used 5' FITC labelled bis-MTX-ASO (**bis-MTX-ASO-FITC**). The nanostructures were prepared with **13DHFR²RGD4C** or **1DHFR²RGD4C** by mixing with **bis-MTX-ASO-FITC** and incubated with $\alpha v \beta 3$ integrin positive MDA-MB-231 breast cancer cells at 37 °C. Green fluorescent punctuates were observed inside the cells treated with either the monomer and multimer nanostructures indicating endocytosis (Figure 2a). Cells treated with **bis-MTX-ASO-FITC** in the absence of DHFR²RGD4C proteins did not show internalized fluorescence (Supplementary, Figure S3). To confirm that the internalization of monomer and multimeric nanostructures are $\alpha v \beta 3$ integrins mediated, competition experiment with excess of commercially available cRGD peptide was performed. **1DHFR²RGD4C** was mixed with **bis-MTX-ASO-FITC** and treated with MDA-MB 231 cells in the presence of excess cRGD peptide and analysed by confocal microscopy. Incubation with cRGD completely blocked the uptake of nanostructures compared to the cells that were not treated with cRGD peptide (Supplementary, Figure S4).

Subcellular co-localization of the oligonucleotide bearing nanostructures was studied by confocal microscopy. cRGD is known to undergo internalization after binding to $\alpha v \beta 3$ by caveolar/lipid raft mediated endocytosis.^{24, 25} **1DHFR²RGD4C** was mixed with **bis-MTX-ASO-FITC** and incubated with MDA-MB 231 cells for 4 hr and 24 hr. During the last 30 min of incubation, cells were treated with Cholera Toxin Alexa Fluor 594 (marker for caveolin endocytosis). Consistent with caveolin-mediated endocytosis, confocal microscopy visualization at 24 hr revealed substantial overlap between fluorescein labelled nanostructures (green) and Alexa Fluor 594 labelled cholera toxin (red) (Figure 2b, Supplementary Figure S5).

Having ascertained the ability of the CSANs-RGD4C nanostructures to deliver oligonucleotides to MDA-MB-231 cells, we probed the ability of the oligonucleotides to escape the endosome and produce an anti-sense effect within the cells. We evaluated the efficacy of anti-sense suppression of eIF4E expression by two different methods: a cellular translational reporter assay and western blot analysis. In this system, cells are transfected with a plasmid that expresses mRNA for the reporter enzyme, *Renilla reniformis* luciferase (RLUC). The translation of RLUC is strictly cap-dependent²⁶ and thus, reflects on the abundance/ activity of eIF4E.²⁷ MDA-MB 231 cells, which transiently expressed luciferase reporter plasmid were treated for 48 hr with CSANs-RGD4C nanostructures containing **bis-MTX-ASO** (or controls). The cells were lysed after the treatment and luciferase activity was measured by luminometry. Luminescence in lysates from untreated cells (neutral control) was set at 100 % (Figure 3). Cells treated with 1 μ M of either **13DHFR²RGD4C**, **1DHFR²RGD4C** or **bis-MTX-ASO** alone (negative controls) showed an approximately

20 % decrease in luminescence levels. Transfection of the cells with 1 μ M ASO with Oligofectamine® (positive control) resulted in a 60 % knock down in luciferase expression. By comparison, delivery of 1 μ M **bis-MTX-ASO** by either **13DHFR²RGD4C** or **1DHFR²RGD4C** reduced the luciferase expression by nearly 65 %. Dose dependence could be observed for the effect of ASO, since treatment of the MDA-MB-231 cells with the **bis-MTX-ASO** and either **13DHFR²RGD4C** or **1DHFR²RGD4C** at the lower concentration of 0.5 μ M monomer resulted in only about 55 % luminescence in both cases. Dose dependent decrease in luminescence was also observed when **1DHFR²RGD4C** was mixed with **bis-MTX-ASO** and treated with MDA-MB 231 cells at concentration ranging from 0.1 μ M to 1 μ M (Supplementary Figure S6). Viability of the cells was determined by quantifying the total amount of protein in the cell lysate by Bradford's protein assay. Control cell viability was found to be greater than 90 % after 48 hr, while 75–80 % of the cells treated with the CSANs-ASO remained viable over the same time period. The minimal reduction in viability shows that the decrease in luminescence is a result of activity by the ASO and not due to a reduction of viability resulting from inherent nanostructure toxicity.

As a secondary measure of antisense activity, western blotting was performed to evaluate the knock down of eIF4E expression in MDA-MB-231 cells (Figure 4). Results were normalized to untreated MDA-MB-231 cells. Treatment with 1 μ M **13DHFR²RGD4C**, **1DHFR²RGD4C** or **bis-MTX-ASO** alone showed no significant decrease in eIF4E expression levels (two sample t-test, $p > 0.01$). Delivery of an oligonucleotide by either **13DHFR²RGD4C** or **1DHFR²RGD4C**, in which the oligonucleotide sequence was scrambled, did not significantly affect eIF4E expression (two sample t-test, $p > 0.01$). Whereas, CSAN- nanostructure (monomer and multimer) directed delivery of ASO resulted in a greater than 50 % reduction in eIF4E expression at a concentration of 1 μ M, which is comparable to the 70 % reduction in eIF4E expression observed for ASO delivered with the Oligofectamine® reagent (two sample t-test, $p > 0.01$). Further, CSANs without RGD4C peptide did not knock down eIF4E expression in MDA-MB 231 cells (data not shown). Viability of the cells was determined by manually counting the cells. Even though the viability of the cells was slightly lower as compared to luciferase assay, the general trend was similar in both the assays.

We have shown that chemically self assembled nanostructures can be modified to display cell targeting peptides, specifically RGD4C, a cyclic peptide targeting integrins found on the surface of solid tumors and neo-vasculature. Modification of the bis-MTX ligand allows for attachment of oligonucleotides which can be delivered to breast cancer cells which over-express α V β 3 integrins. The benefit of using RGD4C as a targeting element is that it consists of natural amino acids and as such can be expressed as part of the DHFR fusion protein in *E.coli* cells. The results of the luciferase reporter assay and western blot analysis of eIF4E levels are consistent with the delivery and endosomal escape of ASO by CSANs-RGD4C nanostructures. The monomeric and multimeric nanostructures showed similar knockdown. This indicates that with the help of CSANs if we keep the concentration of ASO constant, we are able to see similar antisense effect irrespective to whether we use monomeric or multimeric CSANs. There are number of examples in the literature in which the cellular delivery of drugs, oligonucleotides, nanoparticles has been facilitated by

conjugation to cyclic RGD peptides or analogues. For example, Juliano and co workers have recently shown that nucleic acids can be delivered selectively to cancerous cells by conjugation to a semisynthetic RGD based peptide.²⁴ We are also exploring the use of CSANs for the delivery of siRNA, shRNA and miRNA species. In addition, the flexibility and modular nature of CSANs will allow the potential for nucleic acid delivery by scFvs and peptides that target wide range of receptors to be investigated.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the National Institutes of Health (CA120116, CA125360) and the Academic Health Center at the University of Minnesota for financial support.

References

1. Jeong J, Park T, Kim S. Self-Assembled and Nanostructured siRNA Delivery Systems. *Pharmaceutical Research*. 2011; 28(9):2072–2085. [PubMed: 21424157]
2. Bennett CF, Swayze EE. RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform. *Annual Review of Pharmacology and Toxicology*. 2010; 50(1):259–293.
3. Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. *The Journal of Pathology*. 2012; 226(2):365–379. [PubMed: 22069063]
4. Vaishnav AK, Gallob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, Fougerolles T, Maraganore J. A status report on RNAi therapeutics. *Silence*. 2010; 1:1–14. [PubMed: 20226068]
5. Jeong JH, Mok H, Oh Y-K, Park TG. siRNA Conjugate Delivery Systems. *Bioconjugate Chemistry*. 2008; 20(1):5–14.
6. Nakagawa O, Ming X, Huang L, Juliano RL. Targeted Intracellular Delivery of Antisense Oligonucleotides via Conjugation with Small-Molecule Ligands. *Journal of the American Chemical Society*. 2010; 132(26):8848–8849. [PubMed: 20550198]
7. Mashimo Y, Maeda H, Mie M, Kobatake E. Construction of Semisynthetic DNA– Protein Conjugates with Phi X174 Gene-A* Protein. *Bioconjugate Chemistry*. 2012; 23(6):1349–1355. [PubMed: 22616938]
8. Patel PC, Giljohann DA, Seferos DS, Mirkin CA. Peptide antisense nanoparticles. *Proceedings of the National Academy of Sciences*. 2008; 105(45):17222–17226.
9. Keum J-W, Ahn J-H, Bermudez H. Design, Assembly, and Activity of Antisense DNA Nanostructures. *Small*. 2011; 7(24):3529–3535. [PubMed: 22025353]
10. Gangar A, Fegan A, Kumarapperuma SC, Wagner CR. Programmable Self- Assembly of Antibody–Oligonucleotide Conjugates as Small Molecule and Protein Carriers. *Journal of the American Chemical Society*. 2012; 134(6):2895–2897. [PubMed: 22296405]
11. Li Q, Hapka D, Chen H, Vallera DA, Wagner CR. Self-Assembly of Antibodies by Chemical Induction. *Angewandte Chemie*. 2008; 120(52):10333–10336.
12. Li Q, So CR, Fegan A, Cody V, Sarikaya M, Vallera DA, Wagner CR. Chemically Self-Assembled Antibody Nanorings (CSANs): Design and Characterization of an Anti-CD3 IgM Biomimetic. *Journal of the American Chemical Society*. 2010; 132(48):17247–17257. [PubMed: 21077608]
13. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy. *Cancer Research*. 2008; 68(3):631–634. [PubMed: 18245460]
14. Hsieh AC, Ruggero D. Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer. *Clinical Cancer Research*. 2010; 16(20):4914–4920. [PubMed: 20702611]

15. Benedetti AD, Graff JR. eIF-4E expression and its role in malignancies and metastases. *Oncogene*. 2004; 23:3189–3199. [PubMed: 15094768]
16. Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. *The Journal of Clinical Investigation*. 2007; 117(9):2638–2648. [PubMed: 17786246]
17. Dong K, Wang R, Wang X, Lin F, Shen J-J, Gao P, Zhang H-Z. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. *Breast Cancer Research and Treatment*. 2009; 113(3):443–456. [PubMed: 18327707]
18. Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K, Tofilon PJ. Translation Initiation Factor eIF4E Is a Target for Tumor Cell Radiosensitization. *Cancer Research*. 2012; 72(9):2362–2372. [PubMed: 22397984]
19. Goodman SL, Picard M. Integrins as therapeutic targets. *Trends in pharmacological sciences*. 2012; 33(7):405–412. [PubMed: 22633092]
20. Gaertner F, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. *European Journal of Nuclear Medicine and Molecular Imaging*. 2012; 39:126–138.
21. Zhou Y, Shao G, Liu S. Monitoring Breast Tumor Lung Metastasis by U-SPECT- II/CT with an Integrin $\alpha v \beta 3$ -Targeted Radiotracer ^{99m}Tc -3P-RGD2. *Theranostics*. 2012; 2(6):577–588. [PubMed: 22737193]
22. Zhang F, Huang X, Zhu L, Guo N, Niu G, Swierczewska M, Lee S, Xu H, Wang AY, Mohamedali KA, Rosenblum MG, Lu G, Chen X. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. *Biomaterials*. 2012; 33:5414–5422. [PubMed: 22560667]
23. Carlson JCT, Jena SS, Flenniken M, Chou T-f, Siegel RA, Wagner CR. Chemically Controlled Self-Assembly of Protein Nanorings. *Journal of the American Chemical Society*. 2006; 128(23): 7630–7638. [PubMed: 16756320]
24. Alam MR, Ming X, Fisher M, Lackey JG, Rajeev KG, Manoharan M, Juliano RL. Multivalent Cyclic RGD Conjugates for Targeted Delivery of Small Interfering RNA. *Bioconjugate Chemistry*. 2011; 22(8):1673–1681. [PubMed: 21755983]
25. Kagaya H, Oba M, Miura Y, Koyama H, Ishii T, Shimada T, Takato T, Kataoka K, Miyata T. Impact of polyplex micelles installed with cyclic RGD peptide as ligand on gene delivery to vascular lesions. *Gene Therapy*. 2011; 19:61–69. [PubMed: 21654819]
26. Poulin F, Gingras A-C, Olsen H, Chevalier S, Sonenberg N. 4E-BP3, a New Member of the Eukaryotic Initiation Factor 4E-binding Protein Family. *Journal of Biological Chemistry*. 1998; 273(22):14002–14007. [PubMed: 9593750]
27. Ghosh B, Benyumov AO, Ghosh P, Jia Y, Avdulov S, Dahlberg PS, Peterson M, Smith K, Polunovsky VA, Bitterman PB, Wagner CR. Nontoxic Chemical Interdiction of the Epithelial-to-Mesenchymal Transition by Targeting Cap-Dependent Translation. *ACS Chemical Biology*. 2009; 4(5):367–377. [PubMed: 19351181]

Figure 1.

(a) Scheme for the formation of Oligo functionalized monomeric (upper) and multimeric (lower) nanostructures. DHFR²RGD4C contains two DHFR proteins (gray) and cRGD peptide (blue ring with 3 red dots). Bis-MTX-ASO has a bis-MTX, shown in green, attached to the ASO (blue). Size exclusion chromatography (SEC) trace of **13DHFR²RGD4C** (b) or **1DHFR²RGD4C** (c) alone (black) and after incubation with **bis-MTX-ASO** (red)

Figure 2. Subcellular localization by Confocal microscopy: (a) MDA-MB-231 cells: differential interference contrast (first column), FITC fluorescence confocal channel (second column) and overlay of both channels (third column) images for **bis-MTX-ASO-FITC** incubated with either **1DHFR²RGD4C** (upper panel) or **13DHFR²RGD4C** (lower panel) at 37 °C. (b) FITC fluorescence channel for **1DHFR²RGD4C** nanostructures (first column), cholera toxin Alexa Fluor 594 (second column), overlay of green and red channel (third column).

Figure 3.

Translational reporter assay data with cell viability (grey bars) and % expression (white bars) of luciferase in MDA-MB 231 cells at 48 hr, no treatment a; **1DHFR²RGD4C**, b; **13DHFR²RGD4C**, c; **Bis-MTX-ASO**, d; ASO with Oligofectamine, e; 0.5 μ M multimer, f; 1.0 μ M multimer, g; 0.5 μ M monomer, h; 1.0 μ M monomer, i.

Figure 4.

Western blotting data with cell viability (grey bars) and % expression of eIF4E/ actin (white bars) of MDA-MB-231 cells at 48 hr, a; **1DHFR²RGD4C**, b; **13DHFR²RGD4C**, c; **Bis-MTX-ASO**, d; 1.0 μ M multimer scrambled, e; 1.0 μ M monomer scrambled, f; 1.0 μ M ASO with Oligofectamine, g; 1.0 μ M multimer, h; 1.0 μ M monomer, i. (* $p > 0.01$)